Pharmaceutical

Reprieve for WuXi as Biosecure vote likely pushed to 2025

WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europe as the prospect of the Biosecure Act is deterring potential clients.

Dec 17, 2024 - 06:00
Reprieve for WuXi as Biosecure vote likely pushed to 2025
WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europe as the prospect of the Biosecure Act is deterring potential clients.
Read the original article

Tags:

Previous Article

The future of third-party logistics in an evolving biopharmaceutical world

Next Article

Small cell lung cancer: Navigating the global clinical trial landscape

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ADCs dominate with billion-dollar licensing agreements in 2022

ADCs dominate with billion-dollar licensing agreements ...

Oct 5, 2023

Acumen and Lonza to produce Alzheimer’s drug sabirnetug

Acumen and Lonza to produce Alzheimer’s drug sabirnetug

Apr 7, 2024

BioAge secures $170m for obesity therapeutics development

BioAge secures $170m for obesity therapeutics development

Feb 14, 2024